Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis

Natalie A Carter, Elizabeth C Rosser, Claudia Mauri, Natalie A Carter, Elizabeth C Rosser, Claudia Mauri

Abstract

Introduction: Interleukin-10 (IL-10) producing B cells, also known as regulatory B (Breg) cells, play a key role in controlling autoimmunity. Our laboratory and others have demonstrated a pivotal role for Bregs in rheumatological disorders, including experimental models of arthritis and lupus. The aim of this study was to identify the role of endogenous IL-10 secreting B cells in vivo in controlling the induction and disease progression of collagen-induced arthritis (CIA).

Methods: We generated chimeric mice that had IL-10 knocked-out specifically in the B cell population. These mice were compared with wild-type (WT) B cell chimeric mice for their susceptibility to CIA.

Results: Here we report that chimeric mice specifically lacking IL-10 producing B cells (IL-10-/- B cell) developed an exacerbated CIA compared to chimeric wild type B cell (WT B cell) mice. A marked increase in inflammatory Th1 and Th17 cells were detected in IL-10-/-B cell mice compared to WT B cell mice. Furthermore, there was a reduction in IL-10 secreting CD4+ Tr1 cells in these animals.

Conclusions: IL-10 producing B cells restrain inflammation by promoting differentiation of immuno-regulatory over pro-inflammatory T cells and, hence, act to maintain tolerance.

Figures

Figure 1
Figure 1
Lack of endogenous B cell-derived IL-10 results in exacerbated CIA. A. Chimeric mice were generated that lacked IL-10 specifically on B cells. Mean clinical score for CIA and numbers of diseased paws are shown. Data are expressed as mean ± SEM (n = 20, cumulative data from four separate experiments with n = 5 per experimental group). Data were compared by statistical analysis using the Fisher test. * P < 0.05. B. On Day 45 following immunization, mice were bled and the serum levels of total IgG1 and IgG2a CII-specific IgG antibodies were measured by ELISA. Data are expressed as mean ± SEM (n = 20, cumulative data from four separate experiments with n = 5 per experimental group). Data were compared by statistical analysis using the unpaired t test. * P < 0.05. C. The gradation of arthritis was scored from 0 to 4 according to the intensity of lining layer hyperplasia, mononuclear cell infiltration and pannus formation. Data are expressed as mean ± SEM (n = 20, cumulative data from four separate experiments with n = 5 per experimental group). Representative histological sections are also shown.
Figure 2
Figure 2
Lack of B cell-derived IL-10 results in increased Th17 and Th1 responses. A. A total of 35 days after CIA induction, draining lymph node cells were excised and cultured with PMA plus ionomycin in the presence of Brefeldin A for five hours. The intracellular levels of IFNγ and IL-17 were measured. Dot plots are gated on the CD4+ population. B. Numbers indicate percentages or absolute numbers of cells in the quadrants. Data show mean ± SEM (n = 4), representative of four experiments. Data were compared by statistical analysis using the unpaired t test. *** P < 0.001. C. Supernatant was collected from lymph node cells stimulated in vitro for 48 hours with anti-CD3, and then secreted IFNγ and IL-17 was measured by cytokine FlowCytomix kit. Data show mean ± SEM (n = 4), representative of four experiments. Data were compared by statistical analysis using the unpaired t test. ** P < 0.01. D. Additionally, a BD in vivo cytokine capture assay was used to assess in vivo levels of IFNγ over a 12-hour period. The mean levels of IFNγ-conjugated to antibody in serum are shown ± SEM (n = 5), representative of two separate experiments. Data were compared by statistical analysis using the unpaired t test. * P < 0.05.
Figure 3
Figure 3
Lack of B cell-derived IL-10 results in decreased Tr1 responses, however FoxP3+ Tregs are unaffected. A. A total of 35 days after CIA induction, draining lymph node cells were excised and cultured with PMA plus ionomycin in the presence of Brefeldin A for five hours. The CD4+ T cell population was identified using anti-CD4 FITC mAb and intracellular levels of IL-10 were measured. B. Numbers indicate percentages of cells in the quadrants. Data shown mean ± SEM (n = 4), are representative of four experiments. Data were compared by statistical analysis using the unpaired t test. *** P < 0.001. In addition, supernatant was collected from lymph node cells stimulated in vitro for 48 hours with anti-CD3, and then secreted IL-10 was measured by cytokine FlowCytomix kit. Data show mean ± SEM (n = 4), and are representative of four experiments. Data were compared by statistical analysis using the unpaired t test. *** P < 0.001. C. Tregs were assessed using anti-CD25, anti-CD4 and anti-FoxP3 mAb. Numbers indicate percentages of CD4 gated FoxP3+ cells or the absolute number of cells in a draining lymph node. Data show mean ± SEM (n = 4), and are representative of four experiments. D. Spleens were taken from IL-10-/- B cell and WT B cell animals and used to isolate CD25+ Treg cells using Milteyi Biotech magnetic beads. T-effector cells were isolated from immunized WT B6 mice using the same process. The cells were cultured for 72 hours with anti-CD3 antibody (1 μg/ml). For 12 hours before harvesting cells were pulsed with (3H) thymidine. Data shown are mean ± SEM of triplicate wells and are representative of two independent experiments. E. Additionally, a BD in vivo cytokine capture assay was used to assess in vivo levels of IL-2 over a 12-hour period. The mean levels of IL-2-conjugated to antibody in serum are shown ± SEM (n = 4), are representative of two separate experiments. Data were compared by statistical analysis using the unpaired t test.

References

    1. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol. 1996;26:1511–1518. doi: 10.1002/eji.1830260716.
    1. Mauritz NJ, Holmdahl R, Jonsson R, Van der Meide PH, Scheynius A, Klareskog L. Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum. 1988;31:1297–1304. doi: 10.1002/art.1780311012.
    1. Germann T, Szeliga J, Hess H, Storkel S, Podlaski FJ, Gately MK, Schmitt E, Rude E. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA. 1995;92:4823–4827. doi: 10.1073/pnas.92.11.4823.
    1. Mussener A, Litton MJ, Lindroos E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA) Clin Exp Immunol. 1997;107:485–493. doi: 10.1046/j.1365-2249.1997.3181214.x.
    1. Stasiuk LM, Abehsira-Amar O, Fournier C. Collagen-induced arthritis in DBA/1 mice: cytokine gene activation following immunization with type II collagen. Cell Immunol. 1996;173:269–275. doi: 10.1006/cimm.1996.0277.
    1. Holmdahl R, Jansson L, Larsson A, Jonsson R. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand J Immunol. 1990;31:147–157. doi: 10.1111/j.1365-3083.1990.tb02754.x.
    1. Stuart JM, Tomoda K, Yoo TJ, Townes AS, Kang AH. Serum transfer of collagen-induced arthritis. II. Identification and localization of autoantibody to type II collagen in donor and recipient rats. Arthritis Rheum. 1983;26:1237–1244. doi: 10.1002/art.1780261011.
    1. Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA) Clin Exp Immunol. 1998;111:521–526. doi: 10.1046/j.1365-2249.1998.00529.x.
    1. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007;178:7868–7878.
    1. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003;197:489–501. doi: 10.1084/jem.20021293.
    1. Keravala A, Lechman ER, Nash J, Mi Z, Robbins PD. Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther. 2006;8:R91. doi: 10.1186/ar1960.
    1. Finnegan A, Kaplan CD, Cao Y, Eibel H, Glant TT, Zhang J. Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther. 2003;5:R18–24. doi: 10.1186/ar601.
    1. Johansson AC, Hansson AS, Nandakumar KS, Backlund J, Holmdahl R. IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol. 2001;167:3505–3512.
    1. Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, de Waal Malefyt R, de Vries JE, Roncarolo MG. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994;179:493–502. doi: 10.1084/jem.179.2.493.
    1. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol. 1998;161:3299–3306.
    1. Davidson NJ, Fort MM, Muller W, Leach MW, Rennick DM. Chronic colitis in IL-10-/- mice: insufficient counter regulation of a Th1 response. Int Rev Immunol. 2000;19:91–121. doi: 10.3109/08830180009048392.
    1. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3:944–950.
    1. Suri-Payer E, Fritzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin Immunopathol. 2006;28:3–16. doi: 10.1007/s00281-006-0021-8.
    1. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M, Ehrenstein MR, Flavell RA, Mauri C. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. 2011;186:5569–5579. doi: 10.4049/jimmunol.1100284.
    1. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28:639–650. doi: 10.1016/j.immuni.2008.03.017.
    1. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008;224:201–214. doi: 10.1111/j.1600-065X.2008.00661.x.
    1. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118:3420–3430.
    1. Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol. 2008;29:34–40. doi: 10.1016/j.it.2007.10.004.
    1. Watanabe R, Fujimoto M, Ishiura N, Kuwano Y, Nakashima H, Yazawa N, Okochi H, Sato S, Tedder TF, Tamaki K. CD19 expression in B cells is important for suppression of contact hypersensitivity. Am J Pathol. 2007;171:560–570. doi: 10.2353/ajpath.2007.061279.
    1. Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010;184:4801–4809. doi: 10.4049/jimmunol.0902385.
    1. Brackertz D, Mitchell GF, Mackay IR. Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum. 1977;20:841–850. doi: 10.1002/art.1780200314.
    1. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine. 1999;11:1057–1064. doi: 10.1006/cyto.1999.0502.
    1. Busso N, Frasnelli M, Feifel R, Cenni B, Steinhoff M, Hamilton J, So A. Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum. 2007;56:101–107. doi: 10.1002/art.22312.
    1. Williams RO, Mauri C, Mason LJ, Marinova-Mutafchieva L, Ross SE, Feldmann M, Maini RN. Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy. Arthritis Rheum. 1998;41:1806–1812. doi: 10.1002/1529-0131(199810)41:10<1806::AID-ART12>;2-9.
    1. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010–1020. doi: 10.1172/JCI118861.
    1. Rennick DM, Fort MM. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2000;278:G829–833.
    1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397.
    1. Finkelman FD, Morris SC. Development of an assay to measure in vivo cytokine production in the mouse. Int Immunol. 1999;11:1811–1818. doi: 10.1093/intimm/11.11.1811.
    1. Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, Ehrenstein MR, Mauri C. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol. 2009;182:3492–3502. doi: 10.4049/jimmunol.0803052.
    1. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med. 1997;186:1749–1756. doi: 10.1084/jem.186.10.1749.
    1. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med. 1996;184:2271–2278. doi: 10.1084/jem.184.6.2271.
    1. Mauri C, Carter N. Is there a feudal hierarchy amongst regulatory immune cells? More than just Tregs. Arthritis Res Ther. 2009;11:237. doi: 10.1186/ar2752.
    1. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol. 2007;8:1380–1389. doi: 10.1038/ni1541.
    1. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun. 2003;20:281–285. doi: 10.1016/S0896-8411(03)00044-1.
    1. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2005;105:1162–1169.
    1. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev. 2001;182:68–79. doi: 10.1034/j.1600-065X.2001.1820105.x.
    1. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28–50. doi: 10.1111/j.0105-2896.2006.00420.x.
    1. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci USA. 2007;104:14080–14085. doi: 10.1073/pnas.0700326104.
    1. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA. 2004;101:10398–10403. doi: 10.1073/pnas.0403342101.
    1. Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol. 2003;15:246–252. doi: 10.1097/00002281-200305000-00011.
    1. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol. 2008;64:187–199. doi: 10.1002/ana.21438.
    1. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002;16:219–230. doi: 10.1016/S1074-7613(02)00274-1.

Source: PubMed

3
Tilaa